Clinical Trials
25 trialsNCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07492641 2026-05-22
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT06065748 2026-05-05
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT03155997 2026-04-24
monarchE
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT05696626 2026-04-21
ELAINEIII
LeonaBio
Phase 3 Recruiting
NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
NCT02152631 2026-02-06
JUNIPER
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04584853 2026-01-14
POETIC-A
Institute of Cancer Research, United Kingdom
Phase 3 Active not recruiting
NCT02107703 2025-10-21
MONARCH 2
Eli Lilly and Company
Phase 3 Active not recruiting
NCT07190443 2025-09-29
AURA
Japanese Foundation for Cancer Research
Phase 3 Recruiting
NCT04158362 2025-09-22
AMBRE
UNICANCER
Phase 3 Active not recruiting
NCT04752332 2025-07-15
eMonarcHER
Eli Lilly and Company
Phase 3 Terminated
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT06341621 2024-04-10
Rainbow
Fudan University
Phase 3 Recruiting
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting